These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37278183)

  • 1. qTPI: A quasi-toxicity probability interval design for phase I trials with multiple-grade toxicities.
    Ling H; Shi H; Yuan N; Ji Y; Lin X
    Stat Methods Med Res; 2023 Jul; 32(7):1389-1402. PubMed ID: 37278183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials.
    Lee SY
    Trials; 2023 Nov; 24(1):745. PubMed ID: 37990281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity.
    Xu Z; Lin X
    Stat Methods Med Res; 2022 Mar; 31(3):534-548. PubMed ID: 34806915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities.
    Ezzalfani M; Zohar S; Qin R; Mandrekar SJ; Deley MC
    Stat Med; 2013 Jul; 32(16):2728-46. PubMed ID: 23335156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials.
    Mu R; Hu Z; Xu G; Pan H
    BMC Med Res Methodol; 2021 Dec; 21(1):278. PubMed ID: 34895153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
    Shi H; Cao J; Yuan Y; Lin R
    Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of dose selection using multiple surrogates of toxicity as a continuous variable in phase I cancer trial.
    Lee SY; Munafo A; Girard P; Goteti K
    Contemp Clin Trials; 2022 Feb; 113():106657. PubMed ID: 34954097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes.
    Takeda K; Yamaguchi Y; Taguri M; Morita S
    Biom J; 2023 Oct; 65(7):e2200265. PubMed ID: 37309248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
    Takeda K; Morita S; Taguri M
    Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology.
    Lin X; Ji Y
    Stat Methods Med Res; 2021 Mar; 30(3):843-856. PubMed ID: 33327870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.
    Yuan Z; Chappell R; Bailey H
    Biometrics; 2007 Mar; 63(1):173-9. PubMed ID: 17447942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
    Zhang Y; Kutner M; Chen Z
    Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.